{'52WeekChange': -0.86807656,
 'SandP52WeekChange': 0.0644362,
 'address1': '2450 Holcombe Boulevard',
 'address2': 'Suite J-608',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 1.4,
 'askSize': 2200,
 'averageDailyVolume10Day': 181137,
 'averageVolume': 737988,
 'averageVolume10days': 181137,
 'beta': None,
 'beta3Year': None,
 'bid': 1.4,
 'bidSize': 800,
 'bookValue': 1.32,
 'category': None,
 'circulatingSupply': None,
 'city': 'Houston',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 1.44,
 'dayLow': 1.2902,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.215,
 'enterpriseToRevenue': 2.15,
 'enterpriseValue': 8477317,
 'exDividendDate': None,
 'exchange': 'NCM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 1.4614285,
 'fiftyTwoWeekHigh': 13.5,
 'fiftyTwoWeekLow': 0.555,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 10529742,
 'forwardEps': -0.61,
 'forwardPE': -2.1311474,
 'fromCurrency': None,
 'fullTimeEmployees': 7,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.1001,
 'heldPercentInstitutions': 0.24413,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1563753600,
 'lastSplitFactor': '1:25',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/salariuspharma.com',
 'longBusinessSummary': 'Salarius Pharmaceuticals, Inc. a clinical-stage '
                        'biotechnology company, develops epigenetic-based '
                        "cancer treatments. The company's lead candidate is "
                        'Seclidemstat (SP-2577), which is in Phase I/II '
                        'clinical trial for the treatment of advanced solid '
                        'tumors, including prostate, breast, and ovarian '
                        'cancers, as well as Ewing sarcoma. Salarius '
                        'Pharmaceuticals, Inc. has a strategic partnership '
                        'with The University of Utah Research Foundation for '
                        'the exclusive license with respect to patent rights '
                        'protecting SP-2577 and related compounds; HLB Life '
                        'Sciences to develop, produce, manufacture, use, and '
                        'sell the drug in South Korea; and Cancer Prevention '
                        'and Research Institute of Texas for product '
                        'development activities. The company is headquartered '
                        'in Houston, Texas.',
 'longName': 'Salarius Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 17746040,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_330031056',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -7499836,
 'nextFiscalYearEnd': 1640908800,
 'open': 1.4,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '346-772-0346',
 'previousClose': 1.4,
 'priceHint': 4,
 'priceToBook': 0.9848484,
 'priceToSalesTrailing12Months': 4.5015006,
 'profitMargins': -1.90196,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 1.44,
 'regularMarketDayLow': 1.2902,
 'regularMarketOpen': 1.4,
 'regularMarketPreviousClose': 1.4,
 'regularMarketPrice': 1.4,
 'regularMarketVolume': 173317,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 13650800,
 'sharesPercentSharesOut': 0.0721,
 'sharesShort': 984161,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 659038,
 'shortName': 'Salarius Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.0749,
 'shortRatio': 0.95,
 'startDate': None,
 'state': 'TX',
 'strikePrice': None,
 'symbol': 'SLRX',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.482,
 'twoHundredDayAverage': 1.3154317,
 'volume': 173317,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.salariuspharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '77021'}